Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.
Abstract
Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.
참고문헌 (19)
- Rini BI, "Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma : CALGB 90206", J Clin Oncol, 26, pp.5422~5428 (2008)
- Motzer RJ, "Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial", Lancet, 372, pp.449~456 (2008)
- Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma", N Engl J Med, 356, pp.2271~2281 (2007)
- Hutson TE, "Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma", J Clin Oncol, 32, pp.760~767 (2014)
- Sternberg CN, "Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial", J Clin Oncol, 28, pp.1061~1068 (2010)
- Escudier B, "Sorafenib in advanced clear-cell renal-cell carcinoma", N Engl J Med, 356, pp.125~134 (2007)
- Motzer RJ, "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma", J Clin Oncol, 27, pp.3584~3590 (2009)
- Oudard S, "Everolimus(RAD001) : an mTOR inhibitor for the treatment of metastatic renal cell carcinoma", Expert Rev Anticancer Ther, 9, pp.705~717 (2009)
- Iacovelli R, "Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment", Am J Clin Oncol, 37, pp.611~615 (2014)
- Woldu SL, "Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology", Int Urol Nephrol, 46, pp.2127~2132 (2014)
- Hofmann JN, "CKD and risk of renal cell carcinoma:a causal association?", J Am Soc Nephrol, 25, pp.2147~2148 (2014)
- Russo P, "End stage and chronic kidney disease : associations with renal cancer", Front Oncol, 2, pp.28~ (2012)
- Chang A, "Chronic kidney disease in patients with renal cell carcinoma", Adv Chronic Kid-ney Dis, 21, pp.91~95 (2014)
- Shetty AV, "Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies : a single institution experience", Clin Genitourin Cancer, 12, pp.348~353 (2014)
- Neuzillet Y, "Renal cell carcinoma(RCC)in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population", Eur Urol, 60, pp.366~373 (2011)
- Letavernier E, "mToR inhibitors-induced proteinuria : mechanisms, significance, and management", Transplant Rev(Orlando), 22, pp.125~130 (2008)
- Simpson D, "Temsirolimus : in advanced renal cell carcinoma", Drugs, 68, pp.631~638 (2008)
- Kovarik JM, "Influence of hepatic impairment on everolimus pharmacokinetics : implications for dose adjustment", Clin Pharmacol Ther, 70, pp.425~430 (2001)
- Kim KH, "Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency", Eur J Cancer, 50, pp.746~752 (2014)